EVALUATION OFHELICOBACTERPYLORI STOOLANTIGEN (HPSA) AND ITSROLE IN DIAGNOSIS ANDFOLLOWUPOF ERADICATION
|Full paper||Not Available|
With the discovery ofHelicobacterpylori in 1983 byMarshall andWarren, considerable interest has been expressed in relation to its role in many gastroduodenal and extra-gastric disease. H. pylori is commonly associatedwith gastric and duodenal ulcer. Recnet studies suggest that itplays an important cofactor in the development ofgastric adenocarcinoma andprimary antral B-cell lymphoma. Complete regression ofthese lesions has been documentedfollowing eradication of H. pylori by antibiotic therapy.Prior to the fist description of the 13>14C urea breath test (13I14CUBT), the diagnosis ofH. pylori infection had usually been established by histology, culture, or biopsy, or non-invasively by serology. Although 14C/urea breath test is a simple, practical and highly accurate non invasive but needs special laboratory and special technicians in addition to its high cost. Detection ofH. pylori by serology reflects only previous exposure toH. pylori andmay not indicate active or recurrent infection. In addition, because antibody titers can take up to six months to fall after successfil treatment, serology tests can not readily be used to assess theefficacy of new treatment regimens. In this study, we used two different diagnostic modalities, histopathological examination and Helicobacter Pylori StoolAntigen (HPSA) to detect H. pylori in patients before and after treatment. The main task of this work is assessment ofHPSA as a diagnostic tool before and after treat ment ofH. pylori infection.